株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

レミケード・バイオシミラーの世界市場:種類・技術・サービス・用途・地域別の予測

Remicade Biosimilar Market: By Type, By Technology, By Service, By Application, By Region-Forecast 2019-2024

発行 IndustryARC 商品コード 422456
出版日 ページ情報 英文
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.05円で換算しております。
Back to Top
レミケード・バイオシミラーの世界市場:種類・技術・サービス・用途・地域別の予測 Remicade Biosimilar Market: By Type, By Technology, By Service, By Application, By Region-Forecast 2019-2024
出版日: 2018年12月14日 ページ情報: 英文
概要

当レポートでは、世界のレミケード・バイオシミラーの市場について分析し、製品の概要や全体的な市場構造、主な市場促進・抑制要因、種類別・技術別・サービス別・地域別の市場動向見通し (今後6年間分)、市場競争の概況、昨今の資本取引・戦略展開の動き、主要企業のプロファイルなどについて調査・推計しております。

第1章 レミケード・バイオシミラー:市場概要

第2章 エグゼクティブ・サマリー

第3章 市場環境

  • 市場シェア分析
  • 比較分析
  • 製品の相互比較
  • エンドユーザーのプロファイル
  • 上位5社の財務分析

第4章 レミケード・バイオシミラー市場の影響要因

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 課題
  • ポーターのファイブフォース分析

第5章 レミケード・バイオシミラー市場:戦略分析

  • バリューチェーン分析
  • 価格動向分析
  • 市場機会の分析
  • 製品/市場のライフサイクル分析
  • サプライヤー・流通業者

第6章 レミケード・バイオシミラー市場:種類別

  • 遺伝子組み換え型・非グリゴシル化タンパク質
  • 遺伝子組み換え型・グリゴシル化タンパク質
  • ペプチド

第7章 レミケード・バイオシミラー市場:技術別

  • モノクローナル抗体 (MAb) 技術
  • 遺伝子組み換え型DNA技術 (rDNA技術)
  • 核磁気共鳴 (NMR) 技術
  • クロマトグラフィー (色層分析)
  • 電気泳動
  • 質量分析
  • ウェスタンブロット法
  • バイオアッセイ (生物検定)

第8章 レミケード・バイオシミラー市場:サービス別

  • CRAMS (医薬品研究開発・製造受託サービス)
  • 治験

第9章 レミケード・バイオシミラー市場:用途別

  • 血液疾患
  • 腫瘍
  • 慢性疾患/自己免疫疾患
  • 成長ホルモン欠乏症
  • その他

第10章 レミケード・バイオシミラー市場:地域別

  • 欧州 (ドイツ、フランス、イタリア、スペイン、ロシア、英国など)
  • アジア太平洋地域 (中国、日本、インド、韓国など)
  • 北米 (米国、カナダ、メキシコ)
  • 他の国々 (RoW) (ブラジルなど)

第11章 レミケード・バイオシミラー市場:市場変化の方向性

  • 事業拡張
  • 技術開発
  • 企業合併・買収 (M&A)、合弁事業
  • 供給契約

第12章 企業プロファイル

第13章 付録

目次

Remicade biosimilar market globally being driven by primary factors like development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, growing prevalence of chronic diseases among aging population. In addition, increase in adoption of remicade biosimilar in emerging economies such as China, India and others, will create new opportunities for global remicade biosimilar market. However, higher cost of the research and development, and stringent government regulations are the key restraints for global remicade biosimilar market.

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, growing prevalence of chronic diseases among aging population are the prime growth drivers of global remicade biosimilar market. In addition, increase in adoption of remicade biosimilar in emerging economies such as China, India and others, will create new opportunities for global remicade biosimilar market. However, higher cost of the research and development, and stringent government regulations are the key restraints for global remicade biosimilar market.

Geographically European dominated global remicade biosimilar market because of favourable regulatory policies designed by the European Medical Association, high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing prevalence of chronic diseases in developing nations such as China, and India in this region. Among all the application, oncology segment has the highest market share in global remicade biosimilar market due to higher prevalence of cancer patients.

This report identifies the global remicade biosimilar market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global remicade biosimilar market.

This report segments global remicade biosimilar market on the basis of type, technology, service, application, and regional market as follows:

Remicade Biosimilar Market, By Type: Recombinant Non-Glycosylated Protein, Recombinant Glycosylated Protein, and Peptides

Remicade Biosimilar Market, By Technology: Monoclonal Antibodies (MAb) Technology, Recombinant DNA Technology (rDNA), Nuclear Magnetic Resonance (NMR) Technology, Chromatography, Electrophoresis, Mass Spectrometry, Western Blotting, and Bioassay

Remicade Biosimilar Market, By Service: Contract Research and Manufacturing Services (CRAMS), and Clinical Trials

The report has focused study on remicade biosimilar market by basis of application such as: Blood Disorders, Oncology Diseases, Chronic and Autoimmune Diseases, Growth Hormone Deficiencies, and Others

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the remicade biosimilar market. Some of the major companies' profiles in detail are as follows:

Teva Pharmaceutical Industries Ltd.

Synthon Pharmaceuticals, Inc.

LG Life Sciences

Novartis (Sandoz)

Celltrion

Table of Contents

1. Remicade Biosimilar Market - Market Overview

2. Executive Summary

3. Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Remicade Biosimilar Market- Market Forces

  • 4.1. Drivers
    • 4.1.1. Development of efficient and advance technology
    • 4.1.2. Higher expiration patent
  • 4.2. Restraints
    • 4.2.1. Higher cost of research and development
  • 4.3. Opportunities
    • 4.3.1. Emerging economies
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Remicade Biosimilar Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Remicade Biosimilar Market, By Type

  • 6.1. Recombinant Non-Glycosylated Protein
  • 6.2. Recombinant Glycosylated Protein
  • 6.3. Peptides

7. Remicade Biosimilar Market, By Technology

  • 7.1. Monoclonal Antibodies (Mab) Technology
  • 7.2. Recombinant DNA Technology (rDNA Technology)
  • 7.3. Nuclear magnetic resonance (NMR) Technology
  • 7.4. Chromatography
  • 7.5. Electrophoresis
  • 7.6. Mass Spectrometry
  • 7.7. Western Blotting
  • 7.8. Bioassay

8. Remicade Biosimilar Market, By Service

  • 8.1. Contract Research and Manufacturing Services (CRAMS)
  • 8.2. Clinical Trials

9. Remicade Biosimilar Market, By Application

  • 9.1. Blood Disorders
  • 9.2. Oncology Diseases
  • 9.3. Chronic and Autoimmune Diseases
  • 9.4. Growth Hormone Deficiencies
  • 9.5. Others

10. Remicade Biosimilar Market, By Geography

  • 10.1. Europe
    • 10.1.1. Germany
    • 10.1.2. France
    • 10.1.3. Italy
    • 10.1.4. Spain
    • 10.1.5. Russia
    • 10.1.6. U.K.
    • 10.1.7. Rest of Europe
  • 10.2. Asia Pacific
    • 10.2.1. China
    • 10.2.2. India
    • 10.2.3. Japan
    • 10.2.4. South Korea
    • 10.2.5. Rest of Asia-Pacific
  • 10.3. North America
    • 10.3.1. U.S.
    • 10.3.2. Canada
    • 10.3.3. Mexico
  • 10.4. Rest of the World (RoW)
    • 10.4.1. Brazil
    • 10.4.2. Rest of RoW

11. Remicade Biosimilar - Market Entropy

  • 11.1. Expansion
  • 11.2. Technological Developments
  • 11.3. Merger & Acquisitions, and Joint Ventures
  • 11.4. Supply- Contract

12. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

  • 12.1. Teva Pharmaceutical Industries Ltd.
  • 12.2. Synthon Pharmaceuticals, Inc.
  • 12.3. LG Life Sciences
  • 12.4. Novartis (Sandoz)
  • 12.5. Celltrion
  • 12.6. Biocon
  • 12.7. Hospira
  • 12.8. Merck Serono (Merck Group)
  • 12.9. Biogen idec Inc.
  • 12.10. Genentech (Roche Group)

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

13. Appendix

  • 13.1. Abbreviations
  • 13.2. Sources
  • 13.3. Research Methodology
  • 13.4. Bibliography
  • 13.5. Compilation of Expert Insights
  • 13.6. Disclaimer
Back to Top